Epkinly (concluded with pTAP LOI) (epcoritamab)

Numéro de dossier de l’AMC: 22708
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) Relapsed or refractory , DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b), in adult patients, after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
Promoteur/fabricant:
AbbVie Corporation
Numéro de projet de l’AMC:
PC0334-000
Lettre d’entente de l’APP:
Conclusion du processus de négociation: